Respiratory Medicine
Volume 95, Issue 1 , Pages 64-70 , January 2001

Comparison between formoterol 12 μ g b.i.d. and on-demand salbutamol in moderate persistent asthma

  • M. MOLIMARD

      Affiliations

    • Service de Pharmacologie, CHU Pellegrin-Carreire, 33076, Bordeaux Cedex
    • ,
  • J. BOURCEREAU

      Affiliations

    • CTAR, 75013, Paris
    • ,
  • V. LE GROS

      Affiliations

    • Novartis Pharma S.A. 92506, Rueil Malmaison Cedex
    • ,
  • I. BOURDEIX

      Affiliations

    • Novartis Pharma S.A. 92506, Rueil Malmaison Cedex
    • ,
  • F. LEYNADIER

      Affiliations

    • Hôpital Tenon, 75970, Paris Cedex 20
    • ,
  • P. DUROUX

      Affiliations

    • Hôpital Antoine Béclère, 92141, Clamart Cedex, France
    • ,
  • IN ASSOCIATION WITH THE FRENCH FOR-F-01 STUDY GROUP

Received 27 June 2000 ,Accepted 26 September 2000.

References 

    References
  1. Faulds D, Hollingshead LM, Goa KL. Formoterol. a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs. 1991;42:115–137
  2. National Heart Lung and Blood Institute, Global strategy for asthma management and prevention, NHLBI/WHO workshop report, National Heart, Lung and Blood Institute, 1995, 1, 48
  3. Maesen F PV, Smeets JJ, Gubbelmans H LL, Zweers P GMA. Bronchodilator effect of inhaled formoterol vs. salbutamol over 12 hours. Chest. 1990;97:590–594
  4. Chapman KR, Kesten S, Szalai JP. Regular vs. as-needed inhaled salbutamol in asthma control. Lancet. 1994;343:1379–1382
  5. Drazen JM, Israel E, Boushey HA. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. New Engl J Med. 1996;335:841–847
  6. Arvidsson P, Larsson S, Löfdahl C-G. Formoterol, a new long-acting bronchodilator for inhalation. Eur Resp J. 1989;2:325–330
  7. Wallin A, Melander B, Rosenhall L. Formoterol, a new long acting β2agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma. Thorax. 1990;45:259–261
  8. Arvidsson P, Larsson S, Löfdahl C-G. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Resp J. 1991;4:1168–1173
  9. Midgren B, Milander B, Persson G. Formoterol, a new long-acting β2agonist, inhaled twice daily, in stable asthmatic subjects. Chest. 1992;101:1019–1022
  10. Kesten S, Chapman KR, Broder I. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis. 1991;144:622–625
  11. Steffensen I, Faurschou P, Riska H. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Allergy. 1995;50:657–663
  12. FitzGerald JM, Chapman KR, Della Cioppa G. Sustained bronchoprotection, bronchodilation, and symptom control during regular formoterol use in asthma of moderate or greater severity. J Allergy Clin Immunol. 1999;103:427–435
  13. Am Rev Resp Dis. 1987;136:225–244
  14. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85:25–31
  15. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997;155:1283–1289
  16. Busse WW. Long- and short-acting β 2-adrenergic agonists. Effects on airway function in patients with asthma. Arch Intern Med. 1996;156:1514–1520
  17. Crane J, Pearce N, Burgess C, Beasley R. Asthma and the β 2-agonist debate. Thorax. 1995;50:S5–S10
  18. Pauwels RA, Löfdahl C-G, Postma DS. Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations: a 1-year, controlled study. N Engl J Med. 1997;337:1405–1411
  19. Tattersfield AE, Postma DS, Barnes PJ. Exacerbations of asthma. a descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med. 1999;160:594–599
  20. Molimard M, Naline E, Zhang Y. Long- and short-acting β 2-adrenoceptor agonists interactions in human contracted bronchi. Eur Resp J. 1998;11:583–588
  21. Vervloet D, Ekström T, Pela R. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med. 1998;92:836–842
  22. Clauzel A-M, Molimard M, Le Gros V. Use of formoterol dry powder administered for three months via a single-dose inhaler in 1380 asthmatic patients. Invest Allergol Clin Immunol. 1998;8:265–270
  23. Jones PW, Brambilla R, Till MD. Quality of life in patients treated with two long-acting β2-agonists: Formoterol and salmeterol [Astract]. Eur Resp J. 1997;10:3S

PII: S0954-6111(00)90972-7

doi: 10.1053/rmed.2000.0972

Respiratory Medicine
Volume 95, Issue 1 , Pages 64-70 , January 2001

Article Tools